In Silico Designing of Novel Thiazolidine-2-one Derivatives as Dual PDE4/7 Inhibitors for Inflammatory Disorders
Open Access
- 2 November 2017
- journal article
- Published by Chitkara University Publications in Journal of Pharmaceutical Technology, Research and Management
- Vol. 5 (2), 149-162
- https://doi.org/10.15415/jptrm.2017.52010
Abstract
Phosphodiesterase 4 (PDE4) and phosphodiesterase 7 (PDE7), members of PDE super family, catalyse metabolism of secondary messenger cyclic adenosine monophosphate leading to augmented inflammatory processes in pro-inflammatory and immune-modulatory cells. Dual inhibitors of PDE4/7 are a novel class of drug candidates which can regulate pro-inflammatory as well as function of immune T-cell and are particularly beneficial for the treatment of various inflammatory diseases devoid of unwanted actions. Intense efforts have been directed towards the development of effective dual inhibitors of both PDE4 and PDE7, but not much success has been reported till yet. The aim of present study was to design some newer substituted thiazolidine-2-one derivatives as dual inhibitors of PDE4/7 using structure based rational drug design approach. A new series of thiazolidine-2-one analogues were designed and molecular docking was performed using AutoDock Vina to explore the bonding interactions of the designed molecules with the amino acid residues in the active site of target proteins. The docking study indicated that all the substituted thiazolidine-2-one derivatives have appreciable binding interactions with protein residues of both PDE4 and PDE7. The newly designed compounds could be used as lead molecules for development potent and non-toxic dual inhibitors of PDE4/7 for the management of various inflammatory conditions.Keywords
This publication has 28 references indexed in Scilit:
- Effect of Phosphodiesterase 7 (PDE7) Inhibitors in Experimental Autoimmune Encephalomyelitis Mice. Discovery of a New Chemically Diverse Family of CompoundsJournal of Medicinal Chemistry, 2012
- Selective Inhibition of Phosphodiesterase 7 (PDE7) by BRL50481 in Healthy and Ovalbumin-Sensitized Guinea PigsActa Medica Martiniana, 2012
- Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissuesNeuropharmacology, 2010
- Frog2: Efficient 3D conformation ensemble generator for small compoundsNucleic Acids Research, 2010
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α InhibitorJournal of Medicinal Chemistry, 2009
- PDE7 inhibitors as new drugs for neurological and inflammatory disordersExpert Opinion on Therapeutic Patents, 2008
- PDE4 inhibitors as new anti-inflammatory drugs: Effects on cell trafficking and cell adhesion molecules expressionPharmacology & Therapeutics, 2005
- Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: Metabolism-directed optimization studies towards orally bioavailable derivativesBioorganic & Medicinal Chemistry Letters, 2004
- The Synthesis of a Selective PDE4/TNFα InhibitorOrganic Process Research & Development, 2001